Basic Information
AIMed (formerly "Hangzhou Huiyi Dao"), established in December 2019, is a pioneering enterprise that focuses on Medical AI technology. It aims to integrate knowledge from the global life sciences domain with computer science theories to achieve an intelligent transformation of the translational medicine ecosystem.Through global collaboration, AIMed co-develops patented algorithms with top research institutions and has obtained authoritative certification from the U.S. FDA. It is a leading practitioner and explorer of AI Agent products for translational medicine scenarios in China and globally. The PharmaMark AI product series has been adopted by multiple national regulatory agencies and is gradually becoming an essential component in pharmaceutical companies' translational medicine workflows.